Vepdegestrant is anticipated to account for over 34 per cent of the global PROTACs market, generating more than $1.2 billion in sales by 2030 while Arvinas is also aiming to capture a higher market ...
Targeted protein degradation, which is a strategy to destroy cancer-causing proteins, has emerged in recent years as one of the hottest fields in drug discovery. Small molecules known as ...
The oncology market for PROTACs is projected to reach $3.7 billion by 2030, even though there are no FDA approved therapies currently. Protein homeostasis is critical for physiology of cell and their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results